Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Grenoble
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with Rheumatoid Arthritis defined according to ACR/EULAR 2010 or ACR 1987 criteria.
Patients in failure (patient insufficiently responding to anti-TNF treatment DAS28 \> 3.2 whether related to primary biotherapy failure, loss of efficacy (loss of response) or adverse event) of a first bDMARD of the anti-TNF family (Adalimumab, Infliximab, Etanercept, Certolizumab or Golimumab).
Stability of synthetic fund processing for 3 months.
Corticosteroids ≤ 0.1 mg/kg/day without cortisone assault within 3 months.
Effective contraception for patients with reproductive capacity (oral contraceptive, intrauterine device, implant, surgical sterilization or abstinence).
Patients who have dated and signed the consent form for the trial.
Patients affiliated to a social security system.
You may not be if
Contraindication to at least one of the following bDMARDs: Rituximab and/or Abatacept and/or Adalimumab.
Scheduled surgical intervention during the trial.
Difficulties in understanding the French language.
Cognitive function disorders (dementia such as Alzheimer's, etc.).
Patients who cannot be followed up at 12 months.
Psycho-social instability incompatible with regular follow-up (homelessness, addictive behavior, a history of psychiatric pathology or any other comorbidity that would make free and informed consent impossible or limit adherence to the protocol).
Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant woman, parturient, breastfeeding mother, persons deprived of liberty by judicial or administrative decision, persons subject to a legal protection measure).
Patients currently participating in other clinical research or who participated in a clinical trial within one month prior to inclusion.
